ABC Arbitrage SA Increases Stake in Haleon PLC Sponsored ADR $HLN

ABC Arbitrage SA raised its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 159.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,727,350 shares of the company’s stock after buying an additional 1,675,889 shares during the period. Haleon comprises approximately 2.4% of ABC Arbitrage SA’s investment portfolio, making the stock its 12th biggest position. ABC Arbitrage SA owned 0.06% of Haleon worth $24,464,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Golden State Wealth Management LLC lifted its holdings in Haleon by 107.6% during the 2nd quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock valued at $28,000 after buying an additional 1,410 shares in the last quarter. SOA Wealth Advisors LLC. grew its stake in Haleon by 60.5% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock worth $28,000 after acquiring an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department increased its position in shares of Haleon by 167.4% during the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after acquiring an additional 2,051 shares during the period. Pittenger & Anderson Inc. bought a new stake in shares of Haleon during the second quarter valued at approximately $36,000. Finally, Atlantic Union Bankshares Corp boosted its holdings in shares of Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after purchasing an additional 2,758 shares during the period. 6.67% of the stock is owned by institutional investors.

Haleon Stock Up 1.4%

Shares of HLN opened at $11.03 on Wednesday. The company has a market capitalization of $49.12 billion, a price-to-earnings ratio of 28.28 and a beta of 0.19. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The stock’s 50-day moving average price is $10.08 and its 200-day moving average price is $9.68. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HLN shares. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Haleon has a consensus rating of “Moderate Buy” and an average target price of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.